Oruka Therapeutics (NASDAQ:ORKA) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Oruka Therapeutics (NASDAQ:ORKA) from a hold rating to a sell rating in a research report released on Saturday.

Other research analysts also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 12th. BTIG Research reiterated a “buy” rating and issued a $56.00 price target on shares of Oruka Therapeutics in a research report on Monday, September 29th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research report on Monday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th. Finally, Barclays assumed coverage on shares of Oruka Therapeutics in a research report on Monday, October 13th. They issued an “overweight” rating and a $48.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.80.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock opened at $27.48 on Friday. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -9.78 and a beta of -0.29. The company’s 50 day moving average is $17.87 and its 200 day moving average is $13.75. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. Sell-side analysts expect that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Trading of Oruka Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Braidwell LP increased its stake in shares of Oruka Therapeutics by 37.0% in the first quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock worth $16,133,000 after purchasing an additional 424,750 shares in the last quarter. Franklin Resources Inc. grew its stake in Oruka Therapeutics by 40.6% during the second quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock valued at $11,355,000 after acquiring an additional 292,421 shares in the last quarter. Geode Capital Management LLC grew its stake in Oruka Therapeutics by 100.6% during the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after acquiring an additional 354,821 shares in the last quarter. Affinity Asset Advisors LLC grew its stake in Oruka Therapeutics by 10.7% during the second quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock valued at $6,765,000 after acquiring an additional 58,117 shares in the last quarter. Finally, Cable Car Capital LP grew its stake in Oruka Therapeutics by 33.3% during the second quarter. Cable Car Capital LP now owns 600,000 shares of the company’s stock valued at $6,726,000 after acquiring an additional 150,000 shares in the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.